Lixte Biotechnology (NASDAQ:LIXT) Announces Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) released its earnings results on Wednesday. The company reported ($0.33) earnings per share (EPS) for the quarter, Zacks reports.

Lixte Biotechnology Stock Performance

Lixte Biotechnology stock traded up $0.34 during midday trading on Wednesday, hitting $4.75. 118,311 shares of the company’s stock were exchanged, compared to its average volume of 660,311. Lixte Biotechnology has a 12 month low of $0.64 and a 12 month high of $6.26. The company has a market cap of $27.09 million, a PE ratio of -3.68 and a beta of 0.45. The firm has a 50-day moving average of $4.76 and a two-hundred day moving average of $3.29.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LIXT shares. Wall Street Zen raised shares of Lixte Biotechnology to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.